The Discounted Cash Flow (DCF) valuation of Bioatla Inc (BCAB) is (39.63) USD. With the latest stock price at 0.38 USD, the upside of Bioatla Inc based on DCF is -10433.9%.

Is Bioatla a buy or a sell?

Based on the latest price of 0.38 USD and our DCF valuation, Bioatla Inc (BCAB) is a sell. Selling Bioatla stocks now will result in a potential gain of 10433.9%.

Note: valuation result may not be accurate due to the company's negative earnings.

	Range	Selected
WACC / Discount Rate	5.4% - 7.9%	6.6%
Long-term Growth Rate	3.0% - 5.0%	4.0%
Fair Price	(238.05) - (22.30)	(39.63)
Upside	-62173.7% - -5914.9%	-10433.9%

0.38 USD

Stock Price

(39.63) USD

Fair Price

REVENUE & EXPENSES

CAPEX

D&A

WORKING CAPITAL

TERMINAL VALUE

Bioatla DCF Valuation: Revenue & Expenses Forecast

(USD in millions)		Projections

	12-2024	12-2025	12-2026	12-2027	12-2028	12-2029

Revenue	11	12	12	13	13	13
% Growth	-	6%	5%	4%	2%	3%

Cost of goods sold	0	0	0	0	0	0
% of Revenue	0%	0%	0%	0%	0%	0%

Selling, G&A expenses	(22)	(23)	(24)	(25)	(26)	(27)
% of Revenue	199%	199%	199%	199%	199%	199%

Research & Development	(63)	(67)	(70)	(73)	(75)	(77)
% of Revenue	574%	574%	574%	574%	574%	574%

Net interest & other expenses	4	4	5	5	5	5
% of Revenue	38%	38%	38%	38%	38%	38%

Tax expense	0	20	21	22	22	23
Tax rate	0%	27%	27%	27%	27%	27%

Net profit	(70)	(54)	(57)	(59)	(60)	(62)
% Margin	-634%	-463%	-463%	-463%	-463%	-463%